Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies

Pricing and reimbursement strategies for innovative new drugs require significant evidence of beneficial clinical and economic outcomes using cost effectiveness and budget impact models.

Market access and pricing strategies for innovative drugs are more challenging than ever. Although the US government has no direct control over pharma pricing, large agencies such as the Veteran's Administration have a significant indirect influence.

Japan and Germany have the most generous government-led reimbursement systems. The UK system follows stricter criteria while France and Italy provide 100% reimbursement for patients with chronic conditions and partial or no reimbursement for less habitual afflictions.

Read more...

• Pricing and Reimbursement Conference Review (26/04/2010)
• Key Asia Pacific Markets (30/06/2009)
• Pharmaceutical Pricing and Reimbursement (13/05/2008)

• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)
• Monoclonal Antibodies Report (14/10/2008)
• EU Pharmaceutical Forum (11/10/2008)
• Neuropathic Pain (10/10/2008)
• Non-hormonal Treatments for Menopausal Symptoms (10/10/2008)
• Rx-to-OTC Strategies (10/10/2008)
• Asthma (10/10/2008)
• Vaccines for Adults and the Elderly (10/10/2008)

---